Effect of statin therapy on vaspin levels in type 2 diabetic patients
Sayer I Al-Azzam,1 Karem H Alzoubi,1 Jaafar Abu Abeeleh,2 Nizar M Mhaidat,1 Mahmoud Abu-Abeeleh31Department of Clinical Pharmacy, Faculty of Pharmacy, Jordan University of Science and Technology, Irbid, 2Department of Pharmacy, Royal Medical Services, Amman, 3Department of Surgery, Division of Cardi...
Guardado en:
Autores principales: | Al-Azzam SI, Alzoubi KH, Abu Abeeleh J, Mhaidat NM, Abu-Abeeleh M |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2013
|
Materias: | |
Acceso en línea: | https://doaj.org/article/eb835243a019475a80fd6e5a9c9de0e3 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Possible involvement of ROS generation in vorinostat pretreatment induced enhancement of the antibacterial activity of ciprofloxacin
por: Masadeh MM, et al.
Publicado: (2017) -
The treatment of type 2 diabetes in the presence of renal impairment: what we should know about newer therapies
por: Davies M, et al.
Publicado: (2016) -
Effects of irbesartan on serum uric acid levels in patients with hypertension and diabetes
por: Nakamura M, et al.
Publicado: (2014) -
Neuropeptide Y: a potential theranostic biomarker for diabetic peripheral neuropathy in patients with type-2 diabetes
por: Noo Ree Cho, et al.
Publicado: (2021) -
Detemir as a once-daily basal insulin in type 2 diabetes
por: Nelson SE
Publicado: (2011)